张学武 . 痛风关节炎治疗中几个备受关注的问题[J]. 北京大学学报（医学版）, 2021 , 53(6) : 1017 -1019 . DOI: 10.19723/j.issn.1671-167X.2021.06.001
| [1] | Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors[J]. Nat Rev Rheumatol, 2020, 16(7):380-390. |
| [2] | FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout[J]. Arthritis Rheumatol, 2020, 72(6):879-895. |
| [3] | Dalbeth N, Gosling AL, Gaffo A, et al. Gout[J]. Lancet, 2021, 397(10287):1843-1855. |
| [4] | Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout[J]. Arthritis Rheumatol, 2017, 69(9):1903-1913. |
| [5] | Khanna PP, Khanna D, Cutter G, et al. Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: A phase Ⅱ, randomized, double-blind, placebo-controlled trial[J]. Arthritis Rheumatol, 2021, 73(8):1523-1532. |
| [6] | White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout[J]. N Engl J Med, 2018, 378(13):1200-1210. |
| [7] | Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): A multicentre, prospective, randomised, open-label, non-inferiority trial[J]. Lancet, 2020, 396(10264):1745-1757. |
/
| 〈 |
|
〉 |
